Choreo LLC’s Allogene Therapeutics ALLO Stock Holding History

Choreo LLC’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$348K	Buy	142,649 +103,800	+267%	+$208K	﹤0.01%	1159
2025 Q4	$50.9K	Buy	+38,849	New	+$51.2K	﹤0.01%	1534

Other funds holding ALLO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Choreo LLC's ALLO Position: Q1 2026 in Review

Choreo LLC increased its Allogene Therapeutics (ALLO) stake by 267% in Q1 2026, buying an estimated $208K and bringing the position to 142,649 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #1159.

Choreo LLC first reported a position in ALLO in Q4 2025 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

Choreo LLC held 142,649 shares of Allogene Therapeutics worth $348K as of Q1 2026.
Choreo LLC bought 103,800 Allogene Therapeutics shares in Q1 2026, an estimated $208K.
Allogene Therapeutics made up ﹤0.01% of Choreo LLC's portfolio in Q1 2026, its #1159 holding.
Choreo LLC first reported a position in Allogene Therapeutics in Q4 2025 and has held it in 2 quarters since.
208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Choreo LLC's 13F filing for Q1 2026, filed 13 May 2026.